The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. / Rasmussen, Andreas Rosén; Viby, Niels-Erik; Hare, Kristine Juul; Hartmann, Bolette; Thim, Lars; Holst, Jens Juul; Poulsen, Steen Seier.

In: Digestive Diseases and Sciences, Vol. 55, No. 10, 01.10.2010, p. 2785-96.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Rasmussen, AR, Viby, N-E, Hare, KJ, Hartmann, B, Thim, L, Holst, JJ & Poulsen, SS 2010, 'The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin', Digestive Diseases and Sciences, vol. 55, no. 10, pp. 2785-96. https://doi.org/10.1007/s10620-009-1104-x

APA

Rasmussen, A. R., Viby, N-E., Hare, K. J., Hartmann, B., Thim, L., Holst, J. J., & Poulsen, S. S. (2010). The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Digestive Diseases and Sciences, 55(10), 2785-96. https://doi.org/10.1007/s10620-009-1104-x

Vancouver

Rasmussen AR, Viby N-E, Hare KJ, Hartmann B, Thim L, Holst JJ et al. The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Digestive Diseases and Sciences. 2010 Oct 1;55(10):2785-96. https://doi.org/10.1007/s10620-009-1104-x

Author

Rasmussen, Andreas Rosén ; Viby, Niels-Erik ; Hare, Kristine Juul ; Hartmann, Bolette ; Thim, Lars ; Holst, Jens Juul ; Poulsen, Steen Seier. / The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. In: Digestive Diseases and Sciences. 2010 ; Vol. 55, No. 10. pp. 2785-96.

Bibtex

@article{604b19b9d4d0453abfcdc455c3de5ec0,
title = "The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin",
abstract = "Erlotinib, an epidermal-growth-factor receptor inhibitor, belongs to a new generation of targeted cancer therapeutics. Gastrointestinal side-effects are common and have been markedly aggravated when erlotinib is combined with cytostatics. We examined the effects of erlotinib alone and combined with the cytostatic, cisplatin, on the gastrointestinal tract and examined whether glucagon-like peptide-2 (GLP-2), an intestinal hormone with potent intestinotrophic properties, might counteract the possible damaging effects of the treatments.",
keywords = "Animals, Antineoplastic Agents, Atrophy, Body Weight, Cisplatin, Dose-Response Relationship, Drug, Drug Interactions, Female, Gastroenteritis, Gastrointestinal Tract, Glucagon-Like Peptide 2, Mice, Mice, Inbred Strains, Protein Kinase Inhibitors, Quinazolines",
author = "Rasmussen, {Andreas Ros{\'e}n} and Niels-Erik Viby and Hare, {Kristine Juul} and Bolette Hartmann and Lars Thim and Holst, {Jens Juul} and Poulsen, {Steen Seier}",
year = "2010",
month = oct,
day = "1",
doi = "10.1007/s10620-009-1104-x",
language = "English",
volume = "55",
pages = "2785--96",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin

AU - Rasmussen, Andreas Rosén

AU - Viby, Niels-Erik

AU - Hare, Kristine Juul

AU - Hartmann, Bolette

AU - Thim, Lars

AU - Holst, Jens Juul

AU - Poulsen, Steen Seier

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Erlotinib, an epidermal-growth-factor receptor inhibitor, belongs to a new generation of targeted cancer therapeutics. Gastrointestinal side-effects are common and have been markedly aggravated when erlotinib is combined with cytostatics. We examined the effects of erlotinib alone and combined with the cytostatic, cisplatin, on the gastrointestinal tract and examined whether glucagon-like peptide-2 (GLP-2), an intestinal hormone with potent intestinotrophic properties, might counteract the possible damaging effects of the treatments.

AB - Erlotinib, an epidermal-growth-factor receptor inhibitor, belongs to a new generation of targeted cancer therapeutics. Gastrointestinal side-effects are common and have been markedly aggravated when erlotinib is combined with cytostatics. We examined the effects of erlotinib alone and combined with the cytostatic, cisplatin, on the gastrointestinal tract and examined whether glucagon-like peptide-2 (GLP-2), an intestinal hormone with potent intestinotrophic properties, might counteract the possible damaging effects of the treatments.

KW - Animals

KW - Antineoplastic Agents

KW - Atrophy

KW - Body Weight

KW - Cisplatin

KW - Dose-Response Relationship, Drug

KW - Drug Interactions

KW - Female

KW - Gastroenteritis

KW - Gastrointestinal Tract

KW - Glucagon-Like Peptide 2

KW - Mice

KW - Mice, Inbred Strains

KW - Protein Kinase Inhibitors

KW - Quinazolines

U2 - 10.1007/s10620-009-1104-x

DO - 10.1007/s10620-009-1104-x

M3 - Journal article

C2 - 20112065

VL - 55

SP - 2785

EP - 2796

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 10

ER -

ID: 33792663